 |
Titanium dioxide and bisoctrizole |
|---|---|
| Trade Name | |
| Orphan Indication | For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prophyrias, Smith-Lemli-Optiz Syndrome, and Hartnup's Disease |
| USA Market Approval | USA |
| USA Designation Date | 2005-05-25 00:00:00 |
| Sponsor | Orfagen;CRDPF - LANGLADE, 31035 Toulouse Cedex; |
